Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06369246 · ClinicalTrials.gov registry record · Phase 1
PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.
A Phase 1 study of Advanced Prostate Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06369246: Recruiting Phase 1 study of Advanced Prostate Cancer, sponsored by M.D. Anderson Cancer Center.
NCT06369246 is a Phase 1 study of Advanced Prostate Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 70 participants, below the 122-participant average among 6 other Advanced Prostate Cancer trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06369246, a Phase 1 study of Advanced Prostate Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
To look at the safety and effectiveness of stereotactic body radiation therapy (SBRT) in treating advanced or high-risk prostate cancer.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DEVICE Stereotactic Body Radiation Therapy
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-06-27 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 1 |
What NCT06369246 shows while recruiting
NCT06369246 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 122-participant average among 6 other Advanced Prostate Cancer trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Advanced Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Body Radiation Therapy is the first listed.
NCT06369246 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06369246 about?
NCT06369246 is a clinical study titled "PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.". To look at the safety and effectiveness of stereotactic body radiation therapy (SBRT) in treating advanced or high-risk prostate cancer.
What is the current status of trial NCT06369246?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2024-06-27. Estimated completion is 2027-09-01.
What conditions does trial NCT06369246 study?
This clinical trial studies the following conditions: Advanced Prostate Cancer.
What interventions are being tested in trial NCT06369246?
The interventions under investigation include: Stereotactic Body Radiation Therapy (DEVICE).
Who is sponsoring clinical trial NCT06369246?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06369246 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
RECRUITING · Phase 1
-
Engage Psychosocial Intervention for Cancer Symptoms
RECRUITING · NA
-
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
ACTIVE NOT RECRUITING · Phase 2
-
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI